RaQualia Pharma Inc
TSE:4579
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
RaQualia Pharma Inc
Operating Expenses
RaQualia Pharma Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
RaQualia Pharma Inc
TSE:4579
|
Operating Expenses
-¥2.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-3%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Operating Expenses
-¥2.4T
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-5%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Operating Expenses
-¥1.3T
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-11%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Operating Expenses
-¥1.4T
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Operating Expenses
-¥293.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Operating Expenses
-¥1.3T
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
RaQualia Pharma Inc
Glance View
RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. The company is headquartered in Nagoya, Aichi-Ken and currently employs 67 full-time employees. The company went IPO on 2011-07-20. The firm is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The firm is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.
See Also
What is RaQualia Pharma Inc's Operating Expenses?
Operating Expenses
-2.8B
JPY
Based on the financial report for Dec 31, 2025, RaQualia Pharma Inc's Operating Expenses amounts to -2.8B JPY.
What is RaQualia Pharma Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-3%
Over the last year, the Operating Expenses growth was -3%. The average annual Operating Expenses growth rates for RaQualia Pharma Inc have been -15% over the past three years , -14% over the past five years , and -3% over the past ten years .
